Find your path to Jeb
609 people in our graph share verified history with Jeb β schools, employers, funds. One of them is your warm intro.
About
Jeb Keiper has over two decades in biotech leadership and strategic transactions. He was CEO of Nimbus Therapeutics from 2014 to 2025, where the company raised over $600 million and oversaw the zasocitinib deal with Takeda. He earlier held senior business development roles at GSK Oncology and worked at Pfizer, McKinsey, and TransForm Pharmaceuticals.
Invests in
BiotechHealthtechMedical Devices
Experience
- Third Rock VenturesVenture Partnercurrent2026 β presentBoston, Massachusetts, United States
- Strand TherapeuticsDirector Board of Directorscurrent2025 β presentBoston, Massachusetts, United States
- Cardurion PharmaceuticalsMember of the Boardcurrent2018 β presentCambridge, MA
- Nimbus TherapeuticsFormer Chief Executive Officer2025 β 2026
- Nimbus TherapeuticsCEO2018 β 2025Cambridge, MA
- Nimbus TherapeuticsChief Financial Officer2017 β 2018Cambridge, MA
- Nimbus TherapeuticsChief Business Officer2014 β 2018Cambridge, MA
- ROME TherapeuticsBoard Member2019 β 2026Cambridge, Massachusetts, United States
- GlaxoSmithKlineVP, Business Development, GSK Oncology2011 β 2014
- GlaxoSmithKlineHead, Acquisitions and Divestitures2009 β 2011
- GlaxoSmithKlineDirector, WW Business Development2008
- GlaxoSmithKlineDirector, R&D Executive Operations2005 β 2008
- McKinsey & Co.Engagement Manager2004 β 2005
- TransForm PharmaceuticalsBusiness Development Manager2003 β 2004
- Massachusetts General HospitalPharmacy Pharmacoeconomic Analyst2002 β 2003
- McKinsey & Co.Business Analyst2000 β 2002
- Mitsubishi Chemical CompanyEngineering Consultant2000
- PfizerScientist I, Pharmaceutical Sciences1998 β 1999
Skills & more
Languages German, broken
From Jeb's professional profile.
Deals Β· 2
Strand TherapeuticsBoard seat
via Third Rock Ventures Β· filed Mar 2026 Β· $120.1M raise
Cardurion Pharmaceuticals, Inc.Board seat
via Third Rock Ventures Β· filed Nov 2019 Β· $10M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Third Rock Ventures
Frequently asked questions
- Who is Jeb Keiper?
- Jeb Keiper has over two decades in biotech leadership and strategic transactions. He was CEO of Nimbus Therapeutics from 2014 to 2025, where the company raised over $600 million and oversaw the zasocitinib deal with Takeda. He earlier held senior business development roles at GSK Oncology and worked at Pfizer, McKinsey, and TransForm Pharmaceuticals.
- Where does Jeb Keiper work?
- Jeb Keiper is Venture Partner at Third Rock Ventures.
- What does Jeb Keiper invest in?
- Jeb Keiper invests in Biotech, Healthtech, Medical Devices.
- What boards does Jeb Keiper sit on?
- Jeb Keiper holds tracked board seats at Cardurion Pharmaceuticals, Inc., Strand Therapeutics.
- Where did Jeb Keiper go to school?
- Jeb Keiper studied at MIT Sloan School of Management (MBA, Finance, Marketing, Entrepreneurship); Massachusetts Institute of Technology (MS, Chemical Engineering); Massachusetts Institute of Technology (BS, Chemistry).
Same school
Also attended MIT Sloan School of Management774
+ 768 more
Also attended Massachusetts Institute of Technology2,000
+ 1,994 more
Shared employers
Also worked at Cardurion Pharmaceuticals2
Also worked at Nimbus Therapeutics8
+ 2 more
Also worked at GlaxoSmithKline174
+ 168 more
Also worked at McKinsey & Co.2,000
+ 1,994 more




































.jpg)